Halberd Corp.

Develop extra-corporeal treatments of disease

Recent News

  • Halberd Corporation Successfully Conjugates Metallic Particles and Antibodies Against Alzheimer's Disease-Associated Antigens

    Jackson Center, Pennsylvania--(Newsfile Corp. - June 16, 2021) - Halberd Corporation (OTC Pink: HALB) has successfully conjugated Tau, Phosphorylated Tau and Beta Amyloid antibodies with gold-coated iron oxide nanoparticles in a patent-pending process. These three antigens, which are found in Cerebral Spinal Fluid (CSF), are associated with the formation of neurofibrillary tangles concomitant with Alzheimer's Disease. Conjugation of these antibodies with gold-coated iron oxide particles provides the basis for the extracorporeal removal and eradication of these Alzheimer's Disease-associated...

    2021-06-16 8:00 AM EDT
  • Halberd Corporation Undertakes Process Toward the Elimination of Alzheimer's Disease

    Jackson Center, Pennsylvania--(Newsfile Corp. - June 9, 2021) - Halberd Corporation (OTC Pink: HALB) commences experimentations to eradicate three of the principal components of Alzheimer's Disease. By eliminating these three critical antigens, which form the basis for neurofibrillary tangles in the brain, Halberd believes that its patented extracorporeal treatment process can slow or stop the progress of the disease.Dr. Mitchell S. Felder, Halberd Corporation's Chief Technical Officer and the inventor of Halberd's technology, stated, "We believe the most efficient...

    2021-06-09 8:00 AM EDT
  • Halberd Corp. Files Provisional Patent Application Complementing Patented Extracorporeal Radio Frequency/Laser Projects

    Jackson Center, Pennsylvania--(Newsfile Corp. - June 1, 2021) - Halberd Corp. (OTC Pink: HALB) announced the filing of a U. S. joint provisional patent application titled, "Antibody Conjugated Nanoparticle Assay And Treatment For SARS-CoV-2." The innovation is a result of Halberd's Sponsored Research conducted at Arizona State University (ASU). The provisional patent application covers technology developed to facilitate conjugation of metallic nanoparticles with antibodies against various bacteria and SARS-CoV-2, for elimination via radio waves. Additionally, the patent...

    2021-06-01 8:00 AM EDT
  • Halberd Announces Agreement to Retire 192,000,000 Outstanding Common Shares and Acquisition/Joint Venture to Be Announced, in Detail, This Week

    Lake Charles, Louisiana--(Newsfile Corp. - April 6, 2020) - Halberd Corporation (OTC Pink: HALB) announces that it has reached an agreement with shareholders holding 192,000,000 shares of the 482,838,125 reported as currently outstanding. Those shares will be returned to treasury and retired. We are also reducing the authorized shares of common stock to 1,000,000,000.Mr. LeDoux, the new CEO, explained that "perhaps even before becoming compliant with our reporting obligations with OTCMarkets, within the next few days, we will detail the...

    2020-04-06 2:19 PM EDT
  • Halberd Moves Forward - Announces New CEO, Commences Process to Become Current, Holding Company Reorganization

    Lake Charles, Louisiana--(Newsfile Corp. - April 3, 2020) - Halberd Corporation (OTC Pink: HALB) announces that James Christopher LeDoux is the new CEO.Mr. LeDoux explains that "Halberd is now current in its filings with the Colorado Secretary of State. The Colorado state filings include, as a prophylactic measure to assure a smooth transition to its new endeavor, a holding company reorganization. As such, Halberd Corporation as it is currently constituted, is the successor issuer, has a clean slate, is debt-free,...

    2020-04-03 12:33 PM EDT